Disposition of 361 shares by Rothblatt Martine A of United Therapeutics at 277.03 subject to Rule 16b-3
| UTHR Stock | USD 320.37 4.73 1.50% |
Slightly above 52% of United Therapeutics' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding United Therapeutics suggests that some traders are interested. United Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in United Therapeutics. Many technical investors use United Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Filed transaction by United Therapeutics Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at zacks.com
 |
United Therapeutics Fundamental Analysis
We analyze United Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
United Therapeutics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
United Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with United Therapeutics stock to make a market-neutral strategy. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics with similar companies.
Peers
United Therapeutics Related Equities
| LRMR | Larimar Therapeutics | 15.58 | ||||
| REPL | Replimune | 11.15 | ||||
| BPMC | Blueprint Medicines | 8.14 | ||||
| AKRO | Akero Therapeutics | 5.98 | ||||
| NUVL | Nuvalent | 4.66 | ||||
| PCVX | Vaxcyte | 4.53 | ||||
| APLS | Apellis Pharmaceuticals | 3.63 | ||||
| ASND | Ascendis Pharma | 2.72 | ||||
| ALNY | Alnylam Pharmaceuticals | 2.57 | ||||
| LEGN | Legend Biotech | 2.40 | ||||
| RARE | Ultragenyx | 1.98 | ||||
| INCY | Incyte | 1.71 | ||||
| MNKD | MannKind Corp | 1.23 | ||||
| VTYX | Ventyx Biosciences | 0.57 | ||||
| DAWN | Day One | 0.16 | ||||
| KNSA | Kiniksa Pharmaceuticals | 0.29 |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.